BioSpace News Archive

March of Dimes, the leader in the fight for the health of all moms and babies, and longtime partner Anthem Blue Cross and Blue Shield Foundation are working together to tackle America’s maternal and infant health crisis.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.

Qrons Inc., an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to report that the United States Patent and Trademark Office has issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College which is directed to mechanically interlocked,molecules-based materials for 3-D printing.

Strategikon Pharma, a leader in digital business technology to accelerate planning, budgeting, and outsourcing for clinical trials, announced the closing of Series A financing.

Future Market Insights’ global small molecule active pharmaceutical ingredient market report forecasts a prolific nudge through 2021, as increasing demand of high potency drugs and increasing chronic diseases boosts the market demand.

Deep Lens and Alabama Oncology today announced that they have entered into a partnership that will integrate Deep Lens’ artificial-intelligence (AI)-based clinical trial matching solution, VIPER™, into all offices within the Alabama Oncology network.

Agilent Technologies Inc. (NYSE: A) announced today that both the InfinityLab LC/MSD iQ and the Ultivo Triple Quadrupole LC/MS systems have earned the highly-respected Accountability, Consistency and Transparency (ACT) Label from My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’s Neuroscience Investor Conference on Thursday, April 29th at 11:30am ET

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time

Ambu Inc., a rapidly growing medical device maker and pioneer of sterile, single-use endoscopes, announced today that it has received Health Canada clearance for the aScope™ 4 Cysto, the company’s innovative flexible cystoscope platform for urology.